Numerical simulation was introduced to study selective vessel heating using diode laser, Nd:YAG laser, copper vapor laser and pulsed dye laser radiation. The vessels' location depth and size were determined, which could ensure selective heating of the vessels to the coagulation temperature. These results are in good agreement with clinical findings, and the validity of our model is confirmed.
Introduction: Basal cell carcinoma (BCC) is the most prevalent form of non-melanoma skin cancer commonly arising in elderly patients. Currently, many laser systems are applied for the treatment of BCC. However, up to the present, there have been several reports concerning ocular side effects due to the laser procedure in the borders of the periorbital area. This determines the feasibility of testing new laser surgical modes for the management of periorbital BCC. This stuay aimed to estimate both the efficacy, the early post-radiated side effects and long-term outcomes of the CVL treatment of periorbital BCC. Patients and Methods: Two men and 6 women aged 50 to 77 years were diagnosed with periorbital BCC according to the data of both the clinical evaluation and histological examination of the tissue samples taken from the involved area. Six months after the laser treatment, the histological examination of skin samples from the borderline of the irradiated area was made again. All patients were followed for 24 months after the laser treatment of BCC. The laser treatment was administered during one session of copper vapor laser (CVL) (Yakhroma-Med model). The treatment included CVL radiation with a wavelength of 511 nm and 578 nm, in the ratio of 3:2. The power level was set up to 3 W, and the exposure time was equal from 200 to 600 ms. The pulse duration accounted for 15 ns. The diameter of the light spot on the skin surface amounted to 1 mm. Results: Dual-wavelengths CVL treatment of periorbital BCC provided a complete elimination of malignant cells and dysplastic vessels during one procedure. The duration of skin healing amounted to 2-4 weeks. There were neither ocular injuries or pronounced skin side effects nor relapses within 24 months after the laser procedure. Conclusion: CVL treatment of periorbital BCC provides relevant cosmetic results without ocular injuries and relapses.
Introduction: Rhinophyma is recognized as a common and severe skin disease manifested as progressive thickening of the nasal skin due to hypertrophy of the soft tissue. The most severe complication of rhinophyma is telangiectasis. So far the pathogenetic approach for the treatment of rhinophyma should be based on the removal of the dysplastic vessels to provide the appropriate revascularization of the involved skin area. Case Report: This study presented the experience of the treatment of rhinophyma with the copper vapor laser (CVL) designed with the computerized scanner device. A 52-year-old elderly Caucasian male patient with typical clinical signs of rhinophyma was successfully managed during three sessions of CVL treatment. CVL emits light with a wavelength of 578 nm, exposure time of 0.2 seconds. The settings used for the CVL in scanner mode were set at 1.2 W. The scanner device has a hexagonal frame with a maximum width of 12 mm with the distance of 1 mm between centers of laser spots. The CVL treatment resulted in a restoration of the natural appearance of the nose without side effect during 18 months after treatment. Conclusion: The described clinical case demonstrates excellent results of the management of rhinophyma by means of the scanned CVL. CVL treatment was associated with the removal both of dysplastic superficial skin vessels, the solution of the inflammation, decline of the sebum production and the disappearance of the nasal hypertrophy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.